Menu Search
Equities

Renovaro Inc

2Q5:DUS

Renovaro Inc

Actions
  • Price (EUR)0.764
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change-11.16%
  • Beta--
Data delayed at least 15 minutes, as of May 16 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Renovaro Inc., formerly Renovaro BioSciences Inc., is a biotechnology company. The Company is engaged in the research and development of pharmaceutical and biological products for the treatment of cancer, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The Company has a single product candidate as a potential cure for HIV, RENB-HV01, adding two additional pipeline candidates for HIV, RENB-HV12 and RENB-HV21, a pipeline for HBV, RENB-HB01, and with a significant into cancer immune therapies to address high unmet needs from difficult-to-treat solid tumors, RENB-DC11. RENB-HV-01 is a HIV autologous transplant with genetically modified cells. RENB-HV12 is a HIV therapeutic vaccine for potential long-term remission/cure. RENB-HV-21, a treatment for HIV with allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). RENB-HB-01 is an HBV gene therapy candidate.

  • Revenue in USD (TTM)0.00
  • Net income in USD-53.93m
  • Incorporated2011
  • Employees11.00
  • Location
    Renovaro IncCentury City Medical Plaza2080 Century City East, Suite 906LOS ANGELES 90067United StatesUSA
  • Phone+1 (212) 763-0184
  • Fax+1 (845) 818-3588
  • Websitehttps://renovarobio.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		RENB:NAQ since
announced		Transaction
value
Gedi Cube BvDeal completed13 Feb 202413 Feb 2024Deal completed-72.70%--
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.